Biotechnology

Caris' Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore

Curie Oncology expands Caris' collaborative network of oncology institutions focused on research into personalized therapies through precision medicine IRVING, Texas, March 9, 2021 /PRNewswire/ -- Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused o...

2021-03-09 19:30 1983

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

ST. LOUIS, March 8, 2021 /PRNewswire/ -- Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement withShanghai-based...

2021-03-08 22:00 4610

Origin Agritech Ltd Utilized Gene Editing Technology to Create New Corn Traits

BEIJING, March 8, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it has successfully utilized gene editing technology to create new corn traits. Gene editing refers to editing DNA strands by introducing...

2021-03-08 22:00 7473

Changzhou National High-Tech Zone to build 70 new production and service facilities this year

CHANGZHOU, China, March 8, 2021 /PRNewswire/ -- On the morning of February 27th , Changzhou National High-Tech Zone held the groundbreaking ceremony for Phase II of Intersurgical Medical Device (Changzhou) Co., Ltd.'s plant. The ceremony is the first of similar events for zone's 70 planned product...

2021-03-08 17:11 3025

Adlai Nortye Announces Formation of its New Scientific Advisory Board

HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includesRonald M. Evans, PhD (Member of the US Natio...

2021-03-08 09:00 1950

ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide

BOSTON, March 5, 2021 /PRNewswire/ -- ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMabTM platform, to better serve resea...

2021-03-05 20:00 3082

WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration

SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Wellmarker Bio(www.wmbio.co ) announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer d...

2021-03-03 22:00 2179

Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility

WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...

2021-03-03 18:23 2505

Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital

ZHUHAI, China, March 2, 2021 /PRNewswire/ -- Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm. Other new investors include Kunlun Capital, CPE, an...

2021-03-03 11:37 1787

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...

2021-03-03 11:12 1773

Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants

* Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes * Seegene's proprietary high multiplex technology enables detection of 10 different targets * S. Korean firm to research additional versions of variant diagnostic tests SEOUL, South Korea,...

2021-03-03 09:20 1976

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

SEATTLE, March 3, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence inMilan, to increase capacities and implement viral vector su...

2021-03-03 08:00 3618

Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System

Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular an...

2021-03-02 22:00 1586

Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal

HONG KONG, March 2, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "...

2021-03-02 20:00 11198

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...

2021-03-02 18:12 3883

Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)

MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug...

2021-03-02 16:01 5239

CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody

SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...

2021-03-02 13:43 1858

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...

2021-03-02 07:00 4915

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...

2021-03-02 05:05 5510

China Biologic Announces Shareholders' Approval of Merger Agreement

BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...

2021-03-01 21:00 10622
1 ... 328329330331332333334 ... 341

Week's Top Stories